Back to Browse Journals » Patient Preference and Adherence » Volume 2

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

Authors Haya Ascher-Svanum, Baojin Zhu, Douglas E Faries, Jonathan P Lacro, Christian R Dolder, Xiaomei Peng

Published Date March 2008 Volume 2008:2 Pages 67—77

DOI http://dx.doi.org/10.2147/PPA.S2940

Published 13 March 2008

Haya Ascher-Svanum1, Baojin Zhu1, Douglas E Faries1, Jonathan P Lacro2, Christian R Dolder3, Xiaomei Peng1

1Eli Lilly and Company, Outcomes Research, Indianapolis, IN, USA; 2VA San Diego Health Care System and Department of Psychiatry, University of California, San Diego, CA, USA; 3Wingate University School of Pharmacy, Wingate, NC, USA

Objective: To compare adherence and persistence to typical versus atypical antipsychotics and between specific atypical agents in the usual care of schizophrenia and to examine the association between adherence and persistence.

Method: Data were drawn from a 3-year prospective, nonrandomized, noninterventional study of schizophrenia conducted during 1997–2003. Initiators on haloperidol, risperidone, olanzapine, quetiapine, and clozapine with at least 1 year of follow-up were included (n = 878). Adherence (Medication Possession Ratio, MPR) and persistence (time to all-cause medication discontinuation) were assessed using medical record prescription information. Analyses employed multivariate statistics adjusted for group differences.

Results: Overall, 58% of the patients were deemed adherent (MPR >80%). Adherence rates were higher: for atypical (59.4%) than typical antipsychotics (34.5%, p < 0.001), for clozapine (77%) than each comparator excluding olanzapine (p < 0.01), and for olanzapine (64%) than risperidone (57%, p = 0.027) and quetiapine (52%, p = 0.019). Differences between risperidone and quetiapine were not statistically significant. Adherence and persistence were highly correlated (r = 0.957, p < 0.001).

Conclusion: In the usual care of schizophrenia, medication adherence and persistence appear to be highly correlated and to significantly differ between typical and atypical antipsychotics and among atypical agents. The choice of antipsychotic may play a meaningful role in patients’ adherence to and persistence with antipsychotic medications.

Keywords: adherence, persistence, schizophrenia, antipsychotics

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Ascher-Svanum H, Brnabic AJM, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K

Neuropsychiatric Disease and Treatment 2012, 8:113-118

Published Date: 15 March 2012

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries et al

ClinicoEconomics and Outcomes Research 2011, 3:9-14

Published Date: 11 January 2011

Readers of this article also read:

Acceleration training for managing nonalcoholic fatty liver disease: a pilot study

Oh S, Shida T, Sawai A, Maruyama T, Eguchi K, Isobe T, Okamoto Y, Someya N, Tanaka K, Arai E, Tozawa A, Shoda J

Therapeutics and Clinical Risk Management 2014, 10:925-936

Published Date: 7 November 2014

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

Leibert E, Danckers M, Rom WN

Therapeutics and Clinical Risk Management 2014, 10:597-602

Published Date: 29 July 2014

Inhibited bacterial biofilm formation and improved osteogenic activity on gentamicin-loaded titania nanotubes with various diameters

Lin WT, Tan HL, Duan ZL, Yue B, Ma R, He G, Tang TT

International Journal of Nanomedicine 2014, 9:1215-1230

Published Date: 7 March 2014

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

Kamijima K, Hashimoto S, Nagayoshi E, Koyama T

Neuropsychiatric Disease and Treatment 2013, 9:555-565

Published Date: 26 April 2013

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Measurement of ocular surface protection under natural blink conditions

Abelson R, Lane KJ, Angjeli E, Johnston P, Ousler G, Montgomery D

Clinical Ophthalmology 2011, 5:1349-1357

Published Date: 22 September 2011

Increased reactive oxygen metabolites is associated with cardiovascular risk factors and vascular endothelial damage in middle-aged Japanese subjects

Sugiura T, Dohi Y, Takase H, Yamashita S, Tanaka S, Kimura G

Vascular Health and Risk Management 2011, 7:475-482

Published Date: 19 July 2011

Corrigendum - Functional mobility and balance in community dwelling elderly submitted to multisensory versus strength exercises

Alfieri FM, Riberto M, Gatz LS, et al

Clinical Interventions in Aging 2010, 5:363-364

Published Date: 24 November 2010

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

Navin K Kapur, Dominique Ashen, Roger S Blumenthal

Vascular Health and Risk Management 2008, 4:39-57

Published Date: 5 March 2008